Standard
Simvastatin as add-on therapy to interferon β-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial. / Sorensen, Per Soelberg; Lycke, Jan; Erälinna, Juha-Pekka; Edland, Astrid; Wu, Xingchen; Frederiksen, Jette Lautrup; Oturai, Annette; Malmeström, Clas; Stenager, Egon; Sellebjerg, Finn; Sondergaard, Helle Bach; SIMCOMBIN study investigators.
I:
Lancet Neurology, Bind 10, Nr. 8, 2011, s. 691-701.
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
Sorensen, PS, Lycke, J, Erälinna, J-P, Edland, A, Wu, X, Frederiksen, JL, Oturai, A, Malmeström, C, Stenager, E
, Sellebjerg, F, Sondergaard, HB & SIMCOMBIN study investigators 2011, '
Simvastatin as add-on therapy to interferon β-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial',
Lancet Neurology, bind 10, nr. 8, s. 691-701.
https://doi.org/10.1016/S1474-4422(11)70144-2
APA
Sorensen, P. S., Lycke, J., Erälinna, J-P., Edland, A., Wu, X., Frederiksen, J. L., Oturai, A., Malmeström, C., Stenager, E.
, Sellebjerg, F., Sondergaard, H. B., & SIMCOMBIN study investigators (2011).
Simvastatin as add-on therapy to interferon β-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial.
Lancet Neurology,
10(8), 691-701.
https://doi.org/10.1016/S1474-4422(11)70144-2
Vancouver
Sorensen PS, Lycke J, Erälinna J-P, Edland A, Wu X, Frederiksen JL o.a.
Simvastatin as add-on therapy to interferon β-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial.
Lancet Neurology. 2011;10(8):691-701.
https://doi.org/10.1016/S1474-4422(11)70144-2
Author
Sorensen, Per Soelberg ; Lycke, Jan ; Erälinna, Juha-Pekka ; Edland, Astrid ; Wu, Xingchen ; Frederiksen, Jette Lautrup ; Oturai, Annette ; Malmeström, Clas ; Stenager, Egon ; Sellebjerg, Finn ; Sondergaard, Helle Bach ; SIMCOMBIN study investigators. / Simvastatin as add-on therapy to interferon β-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial. I: Lancet Neurology. 2011 ; Bind 10, Nr. 8. s. 691-701.
Bibtex
@article{cb37e34a44dd4f5eb17a3c236b7aee97,
title = "Simvastatin as add-on therapy to interferon β-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial",
abstract = "Treatment of relapsing-remitting multiple sclerosis with interferon beta is only partly effective. We aimed to establish whether add-on of simvastatin, a statin with anti-inflammatory properties, improves this efficacy.",
author = "Sorensen, {Per Soelberg} and Jan Lycke and Juha-Pekka Er{\"a}linna and Astrid Edland and Xingchen Wu and Frederiksen, {Jette Lautrup} and Annette Oturai and Clas Malmestr{\"o}m and Egon Stenager and Finn Sellebjerg and Sondergaard, {Helle Bach} and S{\o}rensen, {Per Soelberg}",
note = "Copyright {\textcopyright} 2011 Elsevier Ltd. All rights reserved.",
year = "2011",
doi = "http://dx.doi.org/10.1016/S1474-4422(11)70144-2",
language = "English",
volume = "10",
pages = "691--701",
journal = "The Lancet Neurology",
issn = "1474-4422",
publisher = "TheLancet Publishing Group",
number = "8",
}
RIS
TY - JOUR
T1 - Simvastatin as add-on therapy to interferon β-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial
AU - Sorensen, Per Soelberg
AU - Lycke, Jan
AU - Erälinna, Juha-Pekka
AU - Edland, Astrid
AU - Wu, Xingchen
AU - Frederiksen, Jette Lautrup
AU - Oturai, Annette
AU - Malmeström, Clas
AU - Stenager, Egon
AU - Sellebjerg, Finn
AU - Sondergaard, Helle Bach
AU - SIMCOMBIN study investigators
N1 - Copyright © 2011 Elsevier Ltd. All rights reserved.
PY - 2011
Y1 - 2011
N2 - Treatment of relapsing-remitting multiple sclerosis with interferon beta is only partly effective. We aimed to establish whether add-on of simvastatin, a statin with anti-inflammatory properties, improves this efficacy.
AB - Treatment of relapsing-remitting multiple sclerosis with interferon beta is only partly effective. We aimed to establish whether add-on of simvastatin, a statin with anti-inflammatory properties, improves this efficacy.
U2 - http://dx.doi.org/10.1016/S1474-4422(11)70144-2
DO - http://dx.doi.org/10.1016/S1474-4422(11)70144-2
M3 - Journal article
VL - 10
SP - 691
EP - 701
JO - The Lancet Neurology
JF - The Lancet Neurology
SN - 1474-4422
IS - 8
ER -
